Cantor Fitzgerald Reaffirms Overweight Rating for Prenetics Global (NASDAQ:PRE)

Prenetics Global (NASDAQ:PRE)‘s stock had its “overweight” rating restated by equities researchers at Cantor Fitzgerald in a research report issued to clients and investors on Wednesday,Benzinga reports. They currently have a $9.00 price target on the stock. Cantor Fitzgerald’s price target would suggest a potential upside of 104.55% from the company’s previous close.

Prenetics Global Stock Up 2.3 %

Shares of NASDAQ PRE traded up $0.10 during midday trading on Wednesday, reaching $4.40. 42,822 shares of the company were exchanged, compared to its average volume of 50,559. The stock’s 50-day moving average price is $4.52 and its 200-day moving average price is $5.17. The stock has a market cap of $40.22 million, a P/E ratio of -1.10 and a beta of -0.18. Prenetics Global has a one year low of $2.85 and a one year high of $7.84.

Prenetics Global (NASDAQ:PRE) last issued its earnings results on Monday, October 7th. The company reported ($0.88) earnings per share (EPS) for the quarter. The firm had revenue of $5.94 million during the quarter. Prenetics Global had a negative return on equity of 16.45% and a negative net margin of 191.73%. On average, equities research analysts anticipate that Prenetics Global will post -3.32 EPS for the current year.

About Prenetics Global

Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies.